Roxithromycin inhibits transforming growth factor-β production by cultured human mesangial cells

Nephrology

Volumn 11, Issue 6, 2006, Pages 524-530

  Yamabe, Hideaki ^a   Shimada, Michiko ^a   Kaizuka, Mitsuaki ^a   Nakamura, Masayuki ^a   Kumasaka, Ryuichiro ^a   Murakami, Rei Ichi ^a   Fujita, Takeshi ^a   Nakamura, Norio ^a   Osawa, Hiroshi ^a   Okumura, Ken ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

Mesangial cell; NF B; Roxithromycin; TGF ; Thrombin; Type IV collagen

Indexed keywords

COLLAGEN TYPE 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN TYROSINE KINASE; ROXITHROMYCIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; CELL CULTURE; CELL DAMAGE; COLORIMETRY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FETUS; HUMAN; HUMAN CELL; INCUBATION TIME; MESANGIUM CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTI-BACTERIAL AGENTS; CELLS, CULTURED; COLLAGEN TYPE IV; DRUG INTERACTIONS; ENZYME ACTIVATION; GENE EXPRESSION; HEMOSTATICS; HUMANS; MESANGIAL CELLS; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; PROTEIN-TYROSINE KINASES; RNA, MESSENGER; ROXITHROMYCIN; THROMBIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 33845623273     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2006.00695.x     Document Type: Article

References (21)

1. Border WA, Okuda S, Languino LR, Sporn MB, Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor β1. Nature 1990; 346: 371-4.
2. MacKay K, Striker LJ, Stauffer JW, Doi T, Agodoa LY, Striker GE. Transforming growth factor-β. Murine glomerular receptors and responses of isolated glomerular cells. J. Clin. Invest. 1989; 83: 1160-67.
3. Kaname S, Uchida S, Ogata E, Kurokawa K. Autocrine secretion of transforming growth factor-β in cultured rat mesangial cells. Kidney Int. 1992; 42: 1319-27.
4. Border WA, Okuda S, Languine LR, Ruoslahti E. Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int. 1990; 37: 689-95.
5. Isaka Y, Brees DK, Ikegaya K et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in the kidney. Nat. Med. 1996; 2: 418-23.
6. Keicho N, Kudoh S. Diffuse panbronchitis: Role of macrolides in therapy. Am. J. Respir. Med. 2002; 1: 119-31.
7. Roberts AB, McCune BK, Sporn MB. TGF-β: Regulation of extracellular matrix. Kidney Int. 1992; 41: 557-9.
8. Roberts AB, Sporn MB. The transforming growth factor-β. In: Sporn MB, Roberts AB (eds). Handbook of Experimental Pharmacology, Peptide Growth Factors and Their Receptors, Vol. 95/I. Heidelberg: Springer-Verlag, 1990; 419-72.
9. Roberts AB, Heine UI, Flanders KC, Sporn MB. TGF-β: Major role in regulation of extracellular matrix. Ann. NY Acad. Sci. 1990; 580: 225-32.
10. Coimbra T, Wiggins R, Noh JW, Merritt S, Phan SH. Transforming growth factor-β production in anti-glomerular basement membrane disease in the rabbit. Am. J. Pathol. 1991; 138: 223-34.
11. Shankland SJ, Scholey JW. Expression of transforming growth factor-β1 during diabetic renal hypertrophy. Kidney Int. 1994; 46: 430-42.
12. Garey KW, Alwani A, Danziger LH, Rubinstein IR. Tissue reparative effects of macrolide antibiotics in chronic inflammatory sinopulmonary diseases. Chest 2003; 123: 261-5.
13. Shimane T, Asano K, Mizutani T, Suzaki H. Inhibitory action of roxithromycin on tumour necrosis factor-alpha production from mast cells in vitro. In Vivo 1999; 13: 503-6.
14. Sugiyama Y, Yanagisawa K, Tominaga SI, Kitamura S. Effect of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur. Respir. J. 1999; 14: 1113-16.
15. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K. Fourteen member macrolides inhibit interleulin-8 release by human eosinophils from atopic donors. Antimicrob. Agents Chemother. 1999; 43: 907-11.
16. Sato E, Nelson DK, Koyama S, Hoyt JC, Robbins RA. Erythromycin modulates eosinophil chemoyactic cytokine production by human lung fibroblast in vitro. Antimicrob. Agents Chemother. 2001; 45: 401-6.
17. Morikawa K, Watabe H, Arake M, Morikawa S. Modulatory effects of antibiotics on cytokine production by human monocytes in vitro. Antimicrob. Agents Chemother. 1996; 40: 1366-70.
18. Tomita H, Osanai T, Toki T et al. Roxithromycin is an inhibitor of human coronary smooth muscle cells proliferation: A potential ability to prevent coronary heart disease. Atherosclerosis 2005; 182: 87-95.
19. Yamabe H, Osawa H, Inuma H et al. Thrombin stimulates production of transforming growth factor-beta by cultured human mesangial cells. Nephrol. Dial. Transplant. 1997; 12: 438-42.
20. Komura E, Tonetti C, Penard-Lacronique V et al. Role of the nuclear factor kappa B pathway in transforming growth factor-beta 1 production in idiopathic myelofibrosis: Possible relationship with FK506 binding protein 51 overexpression. Cancer Res. 2005; 65: 3281-9.
21. Tone A, Shikata K, Sasaki M et al. Erythromycin ameliorates renal injury via anti-inflammatory effects in experimental diabetic rats. Diabetologia 2005; 48: 2402-11.